[
[
[
{"study_indication": "Restless Legs Syndrome", "files": [{"url": "http://www.gsk-clinicalstudyregister.com/files/100310/4656/gsk-100310-clinical-study-report-redact.pdf", "path": "full/e00c2bf70e544c53384ba313deaf88a11b5648e0.pdf", "checksum": "27746b373632e0a6516b570399eeeafc"}], "collaborators": "N/A", "title": "A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety of intermittent dosing of ropinirole in patients with Restless Legs Syndrome (RLS)", "created_at": "January 21, 2016", "generic_name": "ropinirole", "updated_at": "January 21, 2016", "trade_name": "Modutab,ZIPEREVE,ZEPREVE,REPREVE,ADARTREL,REQUIP,Zygara; Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL", "sponsor": "GlaxoSmithKline", "file_urls": ["http://www.gsk-clinicalstudyregister.com/files/100310/4656/gsk-100310-clinical-study-report-redact.pdf"], "phase": "Phase 3"},
{"study_indication": "Herpes Genitalis", "files": [{"url": "http://www.gsk-clinicalstudyregister.com/files/100273/5079/gsk-100273-clinical-study-report-redact.pdf", "path": "full/6855da097ca34de5a5ede3695515f90acad65410.pdf", "checksum": "7a0242380b3d8b85a227bd8cfa291395"}], "collaborators": "N/A", "title": "A Randomized, Double-Blind, Placebo-Controlled, Multicenter 60-Day Study Comparing the Efficacy of Valtrex 1 Gram Once Daily vs. Placebo Once Daily in Reducing Viral Shedding in Immunocompetent Subjects with Recurrent HSV-2 Genital Herpes", "created_at": "February 15, 2016", "generic_name": "valaciclovir", "updated_at": "February 15, 2016", "trade_name": "ZELITREX,Valtrex,RAPIVIR,Novirus", "sponsor": "GlaxoSmithKline", "file_urls": ["http://www.gsk-clinicalstudyregister.com/files/100273/5079/gsk-100273-clinical-study-report-redact.pdf"], "phase": "Phase 4"},
{"study_indication": "Neoplasms, Head and Neck", "files": [{"url": "http://www.gsk-clinicalstudyregister.com/files/100262/4330/gsk-100262-clinical-study-report-redact.pdf", "path": "full/17f5fce3e51f4f3493fecabb86ac22c36ca1f6ef.pdf", "checksum": "1be09bea49e9d8c2bff823210f36148d"}], "collaborators": "N/A", "title": "A Phase I, Open-Label, Multicentre, Dose-escalation Study of Oral GW572016 in Combination with Radiation Therapy and Cisplatin in Patients with Stage III-IV Squamous Cell Carcinoma of the Head and Neck", "created_at": "December 11, 2015", "generic_name": "lapatinib", "updated_at": "December 11, 2015", "trade_name": "Tykerb,Tycerb,Tyverb; Tyverb,Tykerb,Tycerb", "sponsor": "GlaxoSmithKline", "file_urls": ["http://www.gsk-clinicalstudyregister.com/files/100262/4330/gsk-100262-clinical-study-report-redact.pdf"], "phase": "Phase 1"},
{"study_indication": "Alzheimer's Disease", "files": [{"url": "http://www.gsk-clinicalstudyregister.com/files/100193/2402/gsk-100193-clinical-study-report-redact-v02.pdf", "path": "full/65a9a0778def5f8296dd04fdc3efb53641be35be.pdf", "checksum": "3a5d9f7838ffe265872f66b4d7620375"}], "collaborators": "N/A", "title": "A 24 week double-blind, randomised, placebo-controlled, parallel-group dose-ranging study to investigate the effects of rosiglitazone (extended release tablets) on cognition in subjects with mild to moderate Alzheimer's disease", "created_at": "July 02, 2014", "generic_name": "rosiglitazone", "updated_at": "March 03, 2015", "trade_name": "Avandia XR,Avandia; Rosiglitazone XR,Avandia XR,Avandia", "sponsor": "GlaxoSmithKline", "file_urls": ["http://www.gsk-clinicalstudyregister.com/files/100193/2402/gsk-100193-clinical-study-report-redact-v02.pdf"], "phase": "phase 2"},
{"study_indication": "Genital Herpes; HIV infection", "files": [{"url": "http://www.gsk-clinicalstudyregister.com/files/100181/3581/gsk-100181-clinical-study-report-redact.pdf", "path": "full/43d7e525b5c037d20adabaa92263e0308db44043.pdf", "checksum": "a95579a560de180cc871259285ae674d"}], "collaborators": "N/A", "title": "An International, Randomized, Double-Blind, Placebo-Controlled Study of Valaciclovir for the Suppression and Episodic Treatment of Genital HSV Infection in HIV-Infected Persons with CD4+ lymphocyte count <100 cells/mm3.", "created_at": "September 18, 2015", "generic_name": "valaciclovir", "updated_at": "September 18, 2015", "trade_name": "ZELITREX,Valtrex,RAPIVIR,Novirus", "sponsor": "GlaxoSmithKline", "file_urls": ["http://www.gsk-clinicalstudyregister.com/files/100181/3581/gsk-100181-clinical-study-report-redact.pdf"], "phase": "Phase 4"}[
{"study_indication": "Hepatitis A; Hepatitis B", "collaborators": "N/A", "title": "Long-Term Persistence Follow-up Study to Evaluate the Immune Persistence of GSK Biologicals' Combined Hepatitis A / Hepatitis B Vaccine in Healthy Adult Volunteers", "created_at": "June 07, 2016", "generic_name": "Hepatitis A (Inactivated), Hepatitis B (Recombinant) Vaccine", "updated_at": "June 07, 2016", "trade_name": "Twinrix", "sponsor": "GlaxoSmithKline", "file_urls": ["http://www.gsk-clinicalstudyregister.com/files/100556 (Y11)/6366/gsk-100556-c-clinical-study-report-redact.pdf"], "phase": "phase 3"},
{"study_indication": "Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis", "collaborators": "N/A", "title": "Study to show lot-to-lot consistency of Hib-MenAC mixed with Tritanrix\u2122-HBV, its non-inferiority to Tritanrix\u2122-HBV/Hiberix\u2122 with or without Meningitec\u2122, and MenA response in 2, 4, 6 month infants with hepatitis B birth dose", "created_at": "April 19, 2016", "generic_name": "Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine", "updated_at": "July 05, 2016", "trade_name": "Tritanrix HepB/Hiberix", "sponsor": "GlaxoSmithKline", "file_urls": ["http://www.gsk-clinicalstudyregister.com/files/100480/60575/gsk-100480-c-clinical-study-report-redact.pdf"], "phase": "phase 3"},
{"study_indication": "Hepatitis A; Hepatitis B", "collaborators": "N/A", "title": "A double blind randomised, comparative study of the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline Biologicals\u2019 combined hepatitis A - hepatitis B vaccine when administered in healthy adults", "created_at": "June 07, 2016", "generic_name": "Hepatitis A (Inactivated), Hepatitis B (Recombinant) Vaccine", "updated_at": "June 07, 2016", "trade_name": "Twinrix", "sponsor": "GlaxoSmithKline", "file_urls": ["http://www.gsk-clinicalstudyregister.com/files/100551 (EXT Y11)/6367/gsk-100551-c-clinical-study-report-redact.pdf"], "phase": "phase 3"},
{"study_indication": "Pulmonary Disease, Chronic Obstructive", "collaborators": "N/A", "title": "A randomised, double blind, placebo controlled, parellel group study to examine the efficacy, safety, tolerability and systemic pharmacokinetic profile of repeated inhaled doses of GSK159797", "created_at": "August 12, 2016", "generic_name": "milveterol", "updated_at": "August 12, 2016", "trade_name": "Milveterol", "sponsor": "GlaxoSmithKline", "file_urls": ["http://www.gsk-clinicalstudyregister.com/files/100527/60860/gsk-100527-clinical-study-report-redact.pdf"], "phase": "Phase 2"},
{"study_indication": "Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis", "collaborators": "N/A", "title": "Study to show non-inferiority of Tritanrix\u2122-HepB/Hib-MenAC (+/- hepatitis B vaccine at birth) versus Tritanrix\u2122-HepB/Hiberix\u2122 without hepatitis B vacc. at birth for antibody response to all vaccine antigens given in healthy infants", "created_at": "February 23, 2016", "generic_name": "Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine", "updated_at": "February 23, 2016", "trade_name": "Tritanrix HepB/Hiberix", "sponsor": "GlaxoSmithKline", "file_urls": ["http://www.gsk-clinicalstudyregister.com/files/100478/5360/gsk-105239-105245-clinical-study-report-redact.pdf"], "phase": "phase 3"},
{"study_indication": "Pulmonary Disease, Chronic Obstructive", "collaborators": "N/A", "title": "A multicentre, randomised, double-blind, parallel group, 24 week study to compare the effect of salmeterol/fluticasone propionate combination product 50/250mcg, with salmeterol 50mcg both delivered twice daily via DISKUS\u00ae/ACCUHALER\u00ae inhaler on lung function and dyspnoea in subjects with Chronic Obstructive Pulmonary Disease (COPD).", "created_at": "February 10, 2014", "generic_name": "fluticasone propionate/salmeterol", "updated_at": "February 05, 2015", "trade_name": "Serevent", "sponsor": "GlaxoSmithKline", "file_urls": ["http://www.gsk-clinicalstudyregister.com/files/100470/2218/gsk-sco100470-clinical-study-report-redact-v02.pdf"], "phase": "phase 3"},
{"study_indication": "Alzheimer's Disease", "collaborators": "N/A", "title": "An open-label extension to study AVA100193, to assess the long-term safety and efficacy of rosiglitazone (extended release tablets) in subjects with mild to moderate Alzheimer's disease", "created_at": "July 21, 2014", "generic_name": "rosiglitazone", "updated_at": "April 09, 2015", "trade_name": "Avandia XR,Avandia; Avandia XR,Rosiglitazone XR,Avandia", "sponsor": "GlaxoSmithKline", "file_urls": ["http://www.gsk-clinicalstudyregister.com/files/100468/2726/gsk-100468-clinical-study-report-redact-v02.pdf"], "phase": "Phase 2"},
{"study_indication": "Hepatitis B", "collaborators": "N/A", "title": "Comparative study of the immunogenicity and protective efficacy of GlaxoSmithKline Biologicals\u2019 rec-DNA hepatitis B vaccine with or without hepatitis B immunoglobulins (HBIg) in newborns of HBeAg+ mothers.", "created_at": "May 31, 2016", "generic_name": "Hepatitis B Vaccine, Recombinant", "updated_at": "May 31, 2016", "trade_name": "Engerix-B", "sponsor": "GlaxoSmithKline", "file_urls": ["http://www.gsk-clinicalstudyregister.com/files/100450/6298/gsk-100450-clinical-study-report-redact.pdf"], "phase": "phase 4"},
{"study_indication": "Hepatitis B", "collaborators": "N/A", "title": "Long-term Follow-Up studies at Years 16-20, to evaluate the persistence of immune response of GSK Biologicals\u2019 hepatitis B vaccine in newborns of HBeAg+ and HBsAg+ mothers in comparison with a historical control group", "created_at": "May 31, 2016", "generic_name": "Hepatitis B Vaccine, Recombinant", "updated_at": "May 31, 2016", "trade_name": "Engerix-B", "sponsor": "GlaxoSmithKline", "file_urls": ["http://www.gsk-clinicalstudyregister.com/files/100449/6296/gsk-100449-clinical-study-report-redact.pdf"], "phase": "phase 4"},
{"study_indication": "Hepatitis B", "collaborators": "N/A", "title": "Long-Term Follow Up Study at Years 16-20, to Evaluate the Persistence of Immune Response of GlaxoSmithKline Biologicals' Hepatitis B Vaccine in Newborns of HBeAg+ and HBsAg+ Mothers", "created_at": "May 31, 2016", "generic_name": "Hepatitis B Vaccine, Recombinant", "updated_at": "May 31, 2016", "trade_name": "Engerix-B", "sponsor": "GlaxoSmithKline", "file_urls": ["http://www.gsk-clinicalstudyregister.com/files/100448/6294/gsk-100448-clinical-study-report-redact.pdf"], "phase": "phase 4"},
{"study_indication": "Acellular Pertussis; Diphtheria; Tetanus; acellular pertussis", "collaborators": "N/A", "title": "A phase III, double-blinded, randomized, multicenter, clinical study to assess the safety and immunogenicity of GSK Biologicals' Tdap 0.3 mg candidate vaccine when given as a booster dose to healthy school children and adolescents (9-13 years of age), previously vaccinated with a 5th consecutive dose of acellular pertussis-containing vaccine, in studies APV-118 or APV-120", "created_at": "May 27, 2016", "generic_name": "Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine", "updated_at": "May 27, 2016", "trade_name": "Boostrix", "sponsor": "GlaxoSmithKline", "file_urls": ["http://www.gsk-clinicalstudyregister.com/files/100406/004/6277/gsk-100406-004-clinical-study-report-redact.pdf"], "phase": "phase 3"},
{"study_indication": "Varicella", "collaborators": "N/A", "title": "Study in Healthy Children (<2 Years) to Evaluate the Safety and Efficacy of GSK Biologicals' Live Attenuated Varicella Vaccine (VarilrixTM) and of GSK Biologicals' Combined Measles-Mumps-Rubella-Varicella Vaccine", "created_at": "April 22, 2016", "generic_name": "Varicella Vaccine", "updated_at": "April 22, 2016", "trade_name": "Varilrix", "sponsor": "GlaxoSmithKline", "file_urls": ["http://www.gsk-clinicalstudyregister.com/files/100388/5808/gsk-100388-clinical-study-report-redact.pdf"], "phase": "phase 3"},
{"study_indication": "Hepatitis A; Hepatitis B", "collaborators": "N/A", "title": "Evaluate the Effect of Several Risk Factors That Are Likely to Influence the Immunogenicity of GSK Biologicals\u2019 Combined Hepatitis A & B Vaccine, vs Separately Administered Monovalent Hepatitis A and Hepatitis B Vaccines", "created_at": "November 05, 2015", "generic_name": "Hepatitis A (Inactivated), Hepatitis B (Recombinant) Vaccine", "updated_at": "November 05, 2015", "trade_name": "Twinrix", "sponsor": "GlaxoSmithKline", "file_urls": ["http://www.gsk-clinicalstudyregister.com/files/100382/4003/gsk-100382-c-clinical-study-report-redact.pdf"], "phase": "phase 4"},
{"study_indication": "Haemophilus influenzae type b; Neisseria Meningitidis; Neisseria Meningitidis-Haemophilus influenzae      type b Vaccine", "collaborators": "N/A", "title": "Study to assess safety, reactogenicity and immunogenicity of a booster dose of an investigational vaccination regimen and GSK Biologicals Hib-MenC vaccine (co-administered with Infanrix penta) compared to a booster dose of Menjugate (co-administered with Infanrix hexa)", "created_at": "May 27, 2016", "generic_name": "Haemophilus influenzae Type b, Meningococcal C and Y-Tetanus Toxoid Conjugate Vaccine", "updated_at": "May 27, 2016", "trade_name": "MenHibrix", "sponsor": "GlaxoSmithKline", "file_urls": ["http://www.gsk-clinicalstudyregister.com/files/100381/6276/gsk-100381-clinical-study-report-redact.pdf"], "phase": "phase 2"},
{"study_indication": "Influenza", "collaborators": "N/A", "title": "To determine the immunogenicity and reactogenicity of a thiomersal free trivalent influenza split vaccine 2003/2004 or of GSK Biologicals\u2019 standard formulation Influsplit SSW\u00ae/Fluarix\u2122 2003/2004 in children aged from 6 months until 6 years", "created_at": "August 05, 2014", "generic_name": "Influenza Vaccine (Split Virion, Inactivated)", "updated_at": "November 04, 2015", "trade_name": "Fluarix", "sponsor": "GlaxoSmithKline", "file_urls": ["http://www.gsk-clinicalstudyregister.com/files/100351/3984/gsk-100351-clinical-study-report-redact-v02.pdf"], "phase": "phase 3"},
{"study_indication": "Influenza", "collaborators": "N/A", "title": "A phase III double-blind randomized multicentric study to determine the reactogenicity of an investigational influenza vaccine compared to the standard influenza vaccine of GlaxoSmithKline Biologicals\u2019 Influsplit SSW\u00ae/ Fluarix\u2122 2003/2004 in subjects aged over 18 years.", "created_at": "May 31, 2016", "generic_name": "Influenza Vaccine (Split Virion, Inactivated)", "updated_at": "May 31, 2016", "trade_name": "Fluarix", "sponsor": "GlaxoSmithKline", "file_urls": ["http://www.gsk-clinicalstudyregister.com/files/100350-055/6306/gsk-100350-055-clinical-study-report-redact.pdf"], "phase": "phase 3"},
{"study_indication": "Restless Legs Syndrome", "collaborators": "N/A", "title": "An open study to compare the PK and tolerability of ropinirole administered as 5 different new formulations with the standard, marketed formulation in healthy volunteers", "created_at": "January 20, 2016", "generic_name": "ropinirole", "updated_at": "January 20, 2016", "trade_name": "requip", "sponsor": "GlaxoSmithKline", "file_urls": ["http://www.gsk-clinicalstudyregister.com/files/101468/197/4674/gsk-101468-197-clinical-study-report-redact.pdf"], "phase": "Phase 1"},
{"study_indication": "Parkinson Disease", "collaborators": "N/A", "title": "101468/196: A Long-Term, Open-Label Continuation Study of Once Daily Administration of Ropinirole CR Tablets to Patients with Parkinson's Disease who Completed the Previous Ropinirole CR Studies 167 or 164", "created_at": "May 20, 2015", "generic_name": "ropinirole", "updated_at": "May 20, 2015", "trade_name": "Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL", "sponsor": "GlaxoSmithKline", "file_urls": ["http://www.gsk-clinicalstudyregister.com/files/101468/196/2973/gsk-101468-196-clinical-study-report-redact.pdf"], "phase": "phase 3"},
{"study_indication": "Restless Legs Syndrome", "collaborators": "N/A", "title": "A 12 Week, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole in Patients Suffering from Restless Legs Syndrome (RLS).", "created_at": "March 21, 2016", "generic_name": "ropinirole", "updated_at": "March 21, 2016", "trade_name": "requip", "sponsor": "GlaxoSmithKline", "file_urls": ["http://www.gsk-clinicalstudyregister.com/files/101468/194/5625/gsk-101468-194-clinical-study-report-redact.pdf"], "phase": "Phase 3"},
{"study_indication": "Restless Legs Syndrome", "collaborators": "N/A", "title": "A 52 Week Open-Label Extension Study of the Long-Term Safety of Ropinirole in Subjects Suffering from Restless Legs Syndrome (RLS)", "created_at": "April 05, 2016", "generic_name": "ropinirole", "updated_at": "April 05, 2016", "trade_name": "Modutab,ZIPEREVE,ZEPREVE,REPREVE,ADARTREL,REQUIP,Zygara; Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL", "sponsor": "GlaxoSmithKline", "file_urls": ["http://www.gsk-clinicalstudyregister.com/files/101468/192/5774/gsk-101468-192-clinical-study-report-redact.pdf"], "phase": "Phase 3"},
{"study_indication": "Restless Legs Syndrome", "collaborators": "N/A", "title": "A 12 Week, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Ropinirole in Subjects with Restless Legs Syndrome (RLS) Suffering from Periodic Leg Movements of Sleep (PLMS)", "created_at": "December 09, 2015", "generic_name": "ropinirole", "updated_at": "December 09, 2015", "trade_name": "requip", "sponsor": "GlaxoSmithKline", "file_urls": ["http://www.gsk-clinicalstudyregister.com/files/101468/191/4275/gsk-101468-191-clinical-study-report-redact.pdf"], "phase": "Phase 3"},
{"study_indication": "Restless Legs Syndrome", "collaborators": "N/A", "title": "A 12 Week, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole in Patients Suffering from Restless Legs Syndrome (RLS).", "created_at": "March 29, 2016", "generic_name": "ropinirole", "updated_at": "March 29, 2016", "trade_name": "requip", "sponsor": "GlaxoSmithKline", "file_urls": ["http://www.gsk-clinicalstudyregister.com/files/101468/190/5773/gsk-101468-190-clinical-study-report-redact.pdf"], "phase": "Phase 3"}